How does inhibition of TNF alpha differ between monoclonal antibodies (infliximab, adalimumab, golimumab, certolizumab) and receptor fusion proteins (etanercept)? | TK Talk
![958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC 958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC](https://www.trc-canada.com/prod-img/D239583.png)
958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC
![Certolizumab pegol – FDA gave green light to UCB's Cimzia to treat psoriatic arthritis | New Drug Approvals Certolizumab pegol – FDA gave green light to UCB's Cimzia to treat psoriatic arthritis | New Drug Approvals](https://i0.wp.com/origin-ars.els-cdn.com/content/image/1-s2.0-S1521694211000799-gr1.jpg)
Certolizumab pegol – FDA gave green light to UCB's Cimzia to treat psoriatic arthritis | New Drug Approvals
![Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/68/6/805/F2.large.jpg)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases
![Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase | Journal of Medicinal Chemistry Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm101346r/asset/images/medium/jm-2010-01346r_0007.gif)